ITAT allows Biotech R&D expenses as deductible: Sec. 37(1) upheld &D

The ITAT ruled in favor of the assessee, allowing the expenses on Biotechnology Research & Development. The ITAT found that the business had already commenced, expenses were revenue in nature, and aligned with Sec. 37(1) for allowable deductions. Referring to precedents, the ITAT emphasized the unity of control between existing and new ventures. The disallowance was deemed unsustainable, and the AO was directed to re-compute the assessee's income, ultimately allowing the appeal.

---

---

Issues: Disallowance of expenditure on Biotechnology Research & Development before commencement of business for Assessment Year 2013-14.

Assessment Proceedings:
The appeal by the assessee arose from the disallowance of expenditure on Biotechnology Research & Development amounting to Rs.169.60 Lacs for the year. The Assessing Officer held that since the business had not commenced, the expenses were precommencement expenses and not allowable as revenue expenditure. The AO emphasized the need for income generation before allowing expenses as revenue deductions. The AO disallowed the claimed depreciation as well.

Appellate Proceedings:
During the appellate proceedings, the assessee argued that the expenses were revenue in nature, directly related to its business, and included salaries, depreciation, and other costs. The assessee presented a letter from the Ministry of Science and Technology recognizing it for customs and excise duty exemption. However, the CIT(A) upheld the disallowance, citing that the expenses were incurred before the commencement of the business, thus not admissible under Sec. 35(1)(i) without certification from the prescribed authority.

Findings and Adjudication:
The ITAT found that the assessee had an existing business in repairs and maintenance and intended to diversify into biotechnology products. The ITAT noted that the assessee had obtained recognition for in-house R&D activities. The approval by the Department of Scientific and Industrial Research (DSIR) was crucial, indicating the readiness of the assessee to undertake research for new products. The ITAT highlighted that the business had already commenced, and the expenses were predominantly revenue in nature, aligning with Sec. 37(1) for allowable deductions.

The ITAT referred to the Hon'ble Delhi High Court's decision in Jay Engineering Works Ltd. v. CIT, emphasizing the unity of control and interconnection between existing and new ventures for expenditure to be considered revenue. The ITAT distinguished the Hyderabad Tribunal's decision in DCIT v. Bharat Biotech International Ltd, noting its subsequent amendment and lack of relevance to the present case. Ultimately, the ITAT held that the disallowance was not sustainable in law, ordering the AO to re-compute the income of the assessee and allowing the appeal.

In conclusion, the ITAT ruled in favor of the assessee, emphasizing the admissibility of the expenses incurred on Biotechnology Research & Development, given the existing business operations and the readiness to expand into new product lines.

---